Public–Private Partnership in the Development of the Hepatitis B Vaccine in Korea: Implications for Developing Countries

Science, Technology & Society

Volumn 10, Issue 1, 1983, Pages 129-140

  Mahoney, Richard T ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; PUBLIC-PRIVATE PARTNERSHIP; SCIENCE AND TECHNOLOGY; VACCINATION;

ASIA; EASTERN HEMISPHERE; EURASIA; FAR EAST; KOREA; SOUTH KOREA; WORLD;

EID: 19344375723     PISSN: 00936502     EISSN: None     Source Type: Journal    
DOI: 10.1177/097172180401000107     Document Type: Article

References (18)

1. Ahn, D., K. Chung and S. Han. 1998. Building a Scientific Knowledge Base in Biotechnology and Transferring it to Industry: Trends and Issues in the Korean Case.Seoul: Science and Technology Policy Institute.
2. Bloom, B. 2003. Available at http://www.hhmi.org/news/bloom.html, accessed on 23 August 2003.
3. Centers for Disease Control (CDC). 1999. MMWR Weekly, 48 (43):1007, available at http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/mm4843a5.htm, accessed on 23 August 2003.
4. Chung W.K., S.K. Moon, R.K. Gershon, A.M. Prince and A. Popper. 1964.‘Anicteric hepatitis in Korea, II: Serial Histologic Studies’, Archives of International Medicine, 113:535–42.
5. Kettler H., K. White and S. Jordon. 2003.‘Valuing Industry Contributions to Public–Private Partnerships for Health Product Development’. The Initiative on Public–Private Partnerships for Health, Global Forum for Health Research, Geneva, May, http://www.ippph.org.
6. Mahoney, R. 1990.‘Cost of Plasma-derived Hepatitis B Vaccine Production’, Vaccine: 8 (4):397–401.
7. Mahoney, R. and J. Maynard. 1999.‘The Introduction of New Vaccines into Developing Countries’, Vaccine, 17(7–8):646–52.
8. Mahoney, R., A. Pablos-Mendez and S. Ramachandran. 2004.‘The Introduction of New Vaccines into Developing Countries III: The Role of Intellectual Property’, Vaccine, 22(5–6):786–92.
9. Milstien, J. and B. Candries. No date. ‘Economics of Vaccine Development and Implementation: Changes of the Past 20 Years’, available at http://www.who.int/vaccines-access/supply/economics_vaccineproduction.pdf.
10. Mrazek, M.F. and E. Mossialos. 2003.‘Stimulating Pharmaceutical Research and Development for Neglected Diseases’, Health Policy, 64:75–88.
11. Muraskin, W. 1995. The War Against Hepatitis B.Philadelphia: University of Pennsylvania Press.
12. National Institutes of Health (NIH). 2003. Available at http://www.clinicaltrials.gov/ct/gui/show/NCT00002916?order=13, accessed on 25 August 2003.
13. Prince, A.M., H. Fuji and R.K. Gershon. 1964.‘Immunohistochemical studies on the etiology of anicteric hepatitis in Korea’, American Journal of Hygiene, 79:365–81.
14. Prince, A.M. and R.K. Gershon. 1979.‘The Etiology of Chronic Active Hepatitis in Korea’, Yale Journal of Biology and Medicine, 52 (2):159–67.
15. Reich, M.R. (ed.). 1998. ‘International Strategies for Tropical Disease Treatments: Experiences with Praziquantel’. WHO/DAP/CTD/98.5, http://www.who.int/medicines/library/dap/who-dap-ctd-98-5/who-dap-ctd-98-5.pdf (accessed 19 January 2005).
16. Scherer, F.M. and J. Watal. 2002.‘Post-TRIPS Options for Access to Patented Medicines in Developing Nations’, Journal of International Economic Law, 5 (4):913–39.
17. World Health Organization (WHO). 2001.‘Special Theme: Public Private Partnerships for Vaccines and Drugs’, Bulletin of the World Health Organization, 79:693–801.
18. World Health Organization (WHO). 2002. World Health Report 2002.Geneva: WHO.